Intuitive surgical inc(ISRG.US AI Earnings Summary)
ISRG AI Earnings Summary (In-Depth)
2026 Q3
Core Highlights
- Stock Price Reaction: INTUITIVE SURGICAL INC reported strong earnings after the U.S. market close on October 20, 2026. Impacted by a $450M settlement and future instrument price reductions, on the first trading day after earnings, 10/21, the stock closed at $428.12, down 2.26% from the 10/20 close of $438.00. Even though revenue and earnings both exceeded market expectations, management's disclosure of the settlement agreement and the estimated 3% to 5% decline in revenue per procedure from instruments and accessories (I&A) triggered market concerns over long-term margins.
- Against Market Expectations: INTUITIVE SURGICAL INC's Non-GAAP EPS this quarter was $3.00, significantly exceeding the $2.65 TradingView pre-earnings market expectation by approximately 13.2%; revenue of $3.049B was about 4.8% above the $2.91B market expectation. The significant beat in EPS was primarily driven by a better product mix (with the higher-priced da Vinci 5 and SP systems accounting for approximately 65% of total shipments), continued growth in I&A revenue, and the recognition of a one-time $28M tariff refund benefit.
- Against Own Previous Guidance: All financial data this quarter exceeded or met the company's own expectations from the previous quarter. Non-GAAP gross margin reached 69.9%, surpassing the upper end of the previous guidance range of 68% to 69% by approximately 0.9 percentage points; the 2026 full-year procedure growth guidance range was also narrowed and the lower end raised to 14% to 15%.
- In One Sentence: INTUITIVE SURGICAL INC demonstrated resilient operational momentum, with da Vinci 5 and SP platform penetration driving an earnings beat, though the settlement and future I&A price cuts sparked margin concerns, and the stock closed down 2.26% on the first trading day after earnings.
Quarterly Highlights
Non-GAAP EPS significantly beat market expectations, with a surge in the systems business driving overall outperformance.
Significant Non-GAAP EPS Beat: Non-GAAP EPS for the quarter was $3.00, approximately 13.2% higher than the $2.65 TradingView pre-earnings market expectation, representing a 25% year-over-year increase. The primary contributors to the beat were systems revenue growing 30% year-over-year to $769M and a Non-GAAP gross margin of 69.9%, both significantly better than the company's own upper-end guidance.
Total Revenue Up 22% YoY, Accelerated Across Three Main Business Lines: Total revenue for the quarter slightly exceeded $3B. Within this, Instruments & Accessories (I&A) grew 18% YoY to $1.8B, Systems grew 30% YoY to $769M, and Services grew 22% YoY to $482M. Total recurring revenue (I&A plus Services) accounted for 84% of total revenue, reflecting high stability in the subscription-based business model.
Record da Vinci System Shipments, da Vinci 5 and SP Account for 65% of Global Shipments: Global shipments totaled 546 da Vinci systems this quarter, up 28% YoY. This included 315 da Vinci 5 units and 42 SP units (a single-quarter record). The global installed base of da Vinci 5 systems has surpassed 2,000 units, with over 18,000 surgeons trained, indicating continued penetration of the next-generation platform.
International Procedure Volume Up 20% YoY, Accelerated Penetration of Benign Procedures Overseas: da Vinci procedure volume outside the US grew 20% YoY, with Europe up 20%, Asia up 19%, and other markets up 22%. Overseas benign procedure volume grew 41% YoY (compared to 37% in Q2 and 34% in Q1), now accounting for over a quarter of international volume, showing that ISRG's expansion into non-urologic oncology fields is accelerating.
Non-GAAP Gross Margin at 69.9%, 0.9 Percentage Points Above Guidance Ceiling: Non-GAAP gross margin was 69.9% this quarter, approximately 0.9 percentage points higher than the 69% upper limit of the full-year guidance provided last quarter (includes a $28M one-time tariff refund; excluding this, it was 68.9%, a 90 bps YoY increase). The improvement was mainly driven by lower product costs and fixed-cost leverage.
Ion Platform Procedure Volume Up 31% YoY, Insurance Coverage Secured in South Korea: Ion procedure volume grew 31% YoY this quarter, with the US up 29%. This quarter, the Ion platform secured health insurance reimbursement eligibility in South Korea. Ion systems are now installed in 12 countries outside the US, and a new manufacturing facility in Penang, Malaysia, is expected to start production in 2028, laying the foundation for long-term international expansion.
SP Single-Port Platform Procedure Volume Up 55% YoY, Global Installed Base Up 42% YoY: SP procedure volume grew 55% YoY this quarter, with the US up 50% and South Korea up 40%. The global SP installed base reached 487 units (up 42% YoY). The SP stapler continues to see expanded adoption, and management plans to submit a 510(k) application to the FDA for the SP vessel sealer in Q4, which is expected to further broaden the indications for the SP platform.
Large-Scale Share Repurchase Demonstrates Active Capital Allocation: The company repurchased $2.9B of stock at an average price of $377 per share this quarter, the largest single-quarter repurchase in the company's history. The period-end cash and investment balance was $6.8B. Despite the decrease from the previous quarter's $8.6B balance, management maintains high confidence in long-term growth.